APA (7th ed.) Citation

Fox, E., Lovett-Racke, A. E., Gormley, M., Liu, Y., Petracca, M., Cocozza, S., . . . Inglese, M. (2021). A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis. Multiple sclerosis, 27(3), 420. https://doi.org/10.1177/1352458520918375

Chicago Style (17th ed.) Citation

Fox, Edward, et al. "A Phase 2 Multicenter Study of Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Patients with Relapsing Forms of Multiple Sclerosis." Multiple Sclerosis 27, no. 3 (2021): 420. https://doi.org/10.1177/1352458520918375.

MLA (9th ed.) Citation

Fox, Edward, et al. "A Phase 2 Multicenter Study of Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Patients with Relapsing Forms of Multiple Sclerosis." Multiple Sclerosis, vol. 27, no. 3, 2021, p. 420, https://doi.org/10.1177/1352458520918375.